The highest FDA-approved dose of bupropion is 450 mg per day, but that number applies specifically to the extended-release (XL) and immediate-release (IR) formulations. The sustained-release (SR) version has a lower ceiling of 400 mg per day. These caps were set primarily because seizure risk climbs with dose, and the difference between therapeutic and dangerous territory is narrower with bupropion than with most other antidepressants. Which formulation you take, how your liver processes the drug, and whether you have kidney or liver problems all change what “the highest allowed dose” actually means for you in practice.
How the Maximum Differs by Formulation
Bupropion comes in three oral formulations, and each has its own dosing ceiling because each releases the drug into your bloodstream at a different speed. The immediate-release (IR) version hits peak blood levels in roughly 1.5 hours, the sustained-release (SR) in about 3 hours, and the extended-release (XL) in around 5 hours.1Clinical Therapeutics. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations That timing matters because bupropion’s most worrying side effect, seizures, is tied to how high your peak blood concentration gets. A fast, tall spike is riskier than a slow, broad one.
For the IR formulation, no single dose should exceed 150 mg, and the daily total tops out at 450 mg split into three doses taken at least six hours apart. The SR formulation caps each dose at 200 mg, with a daily maximum of 400 mg taken as two doses at least eight hours apart. The XL formulation allows a single daily dose of up to 450 mg, taken once in the morning. Most prescribers start well below these ceilings and increase gradually, partly to let your body adapt and partly because many people respond at 300 mg per day or less.
Why the Seizure Risk Drives the Cap
Bupropion was briefly pulled from the U.S. market in the 1980s after an unexpectedly high rate of seizures showed up in clinical trials. The drug returned with stricter dosing rules and a firm daily ceiling. At doses up to 450 mg per day taken as directed, the seizure incidence is roughly comparable to other antidepressants. Exceed that dose, skip the spacing between doses, or combine bupropion with other factors that lower the seizure threshold, and the risk rises sharply.
The relationship is not perfectly linear, but it is clearly dose-dependent. This is why the prescribing rules are unusually specific about both the size of each individual dose and the minimum hours between doses. Crushing or chewing an extended-release tablet, for example, dumps the full dose into your system at once, turning a slow-release formulation into a fast-release one and defeating the purpose of the XL design.
The 450 mg Single Tablet
For years, anyone prescribed 450 mg of bupropion XL had to take three 150 mg tablets at the same time. A single 450 mg extended-release tablet was eventually developed, and pharmacokinetic testing showed it to be bioequivalent to three 150 mg XL tablets taken together. The researchers also simulated what would happen if a patient switched from the three-tablet regimen under fasting conditions to the single tablet taken with food, a scenario they described as a worst case for peak blood levels. Even under those conditions, the switch did not produce a higher peak concentration, meaning it did not increase seizure risk.2International Journal of Clinical Pharmacology & Toxicology. Steady State Plasma Levels of Bupropion After Administration of 3×150 Mg Extended Release Reference Tablets and Switching to 1×450 Mg Extended Release 450ER Tablets
The practical advantage is convenience and adherence. Juggling three tablets can lead to missed or mistimed doses, and a single pill simplifies the routine. If your prescriber has you at the 450 mg ceiling and you are taking multiple tablets, it is worth asking whether the single-tablet version is available to you.
Is There Evidence That Going Above 300 mg Helps More?
You might assume that a well-studied drug would have clear data comparing its standard dose range (300 mg or less) to its high dose range (301 to 450 mg). Surprisingly, the evidence is thin. A systematic search by Canadian health technology reviewers looking specifically for studies comparing high-dose bupropion (301 to 450 mg per day) against standard-dose bupropion for depression turned up nothing that met their inclusion criteria. No head-to-head trials, no evidence-based guidelines with specific high-dose recommendations.3Canadian Journal of Health Technologies. High-Dose Bupropion for Depression
That does not mean 450 mg never helps. Clinicians routinely increase the dose to 450 mg when a patient has had a partial response at 300 mg, and many patients do improve. But the formal evidence base for that move is largely clinical experience rather than controlled trials. This is an unusual gap for a drug that has been on the market for decades, and it means the 450 mg ceiling is more about safety data than proven additional efficacy.
Your Genetics Change the Effective Dose
Bupropion itself is actually a prodrug in some respects: much of its therapeutic activity comes from a metabolite called hydroxybupropion, which is produced by a liver enzyme called CYP2B6. Genetic variation in the gene coding for that enzyme is common, and it meaningfully shifts how much hydroxybupropion your body makes from a given dose of bupropion.4PubMed Central. CYP2B6 and bupropion’s smoking-cessation pharmacology: the role of hydroxybupropion
People who carry certain CYP2B6 variants, particularly the *6 allele, produce less hydroxybupropion. A meta-analysis found that carriers of this variant had roughly 23% lower exposure to hydroxybupropion and about 19% lower exposure to the combined active drug compared to non-carriers.5PubMed. Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis Studies looking at both enantiomers of the drug have confirmed that this genetic variation consistently reduces hydroxylation at steady state, not just after a single dose.6Drug Metabolism and Disposition. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion7PubMed Central. Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition
What this means practically is that two people taking the same dose of bupropion can have very different amounts of active drug in their blood. A “slow metabolizer” might need a higher bupropion dose to reach the same hydroxybupropion level as a normal metabolizer. Conversely, a fast metabolizer could be getting more active metabolite than expected from a standard dose. Pharmacogenomic testing for CYP2B6 is available but not yet routine in most clinical settings. Researchers have suggested that targeting a hydroxybupropion blood level of around 0.7 micrograms per milliliter could improve smoking cessation outcomes, and a similar approach could theoretically guide dosing for depression.4PubMed Central. CYP2B6 and bupropion’s smoking-cessation pharmacology: the role of hydroxybupropion
Therapeutic Drug Monitoring as a Dosing Guide
Rather than relying solely on milligrams per day, some clinicians use blood levels of hydroxybupropion to guide dosing. Research on depressed patients found that those who improved markedly had significantly higher hydroxybupropion blood levels than those with only moderate or minimal improvement. Analysis identified a threshold of roughly 858 ng/mL of hydroxybupropion as a predictor of marked improvement.8PubMed. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion This is still far from standard practice, but it suggests that for patients who are not responding well at 300 mg, checking blood levels before increasing to 450 mg could help distinguish between “needs more drug” and “metabolizes differently.”
Lower Ceilings for Special Populations
The 450 mg cap assumes healthy adult kidney and liver function. Several groups need lower maximum doses, and in some of them the difference is dramatic.
Kidney Impairment
Bupropion exposure roughly doubles in people with significant kidney disease. A study comparing renally impaired patients to healthy controls found that the area under the curve (a measure of total drug exposure) was about 126% higher, peak blood levels were 86% higher, and the drug’s half-life was 140% longer in the impaired group.9PubMed Central. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites The metabolites were less affected, but the parent drug itself lingered far longer. Standard guidance calls for reducing both dose and frequency in patients with impaired kidney function, though specific recommendations vary by formulation and degree of impairment.
Liver Impairment
Since bupropion relies heavily on liver metabolism, liver disease predictably raises blood levels and slows clearance of both the drug and its metabolites. Prescribing guidelines generally recommend lower starting doses and lower maximum doses for patients with hepatic impairment, with severe liver disease typically warranting every-other-day dosing for some formulations. The specific adjustments depend on the severity, but the principle is straightforward: less liver capacity means less drug clearance, which means the same dose hits harder.
Older Adults
Elderly patients clear bupropion and its metabolites more slowly, and the metabolites tend to accumulate. Clinical reports have found that lower doses in the range of 75 to 225 mg per day produce fewer side effects with comparable efficacy to higher doses in older adults.10Jefferson Journal of Psychiatry. The Efficacy and Toxicity of Bupropion in the Elderly A naturalistic study of elderly patients treated with bupropion SR found the average maximum daily dose was 240 mg, with a range of 150 to 400 mg.11PubMed. Bupropion SR in the naturalistic treatment of elderly patients with major depression In a separate trial of elderly patients with depression and other medical conditions, bupropion SR was dosed up to 150 mg twice daily, and the average dose at the end of the study was 222 mg per day. The drug was generally well tolerated at that level, with no drug interactions observed.12PubMed Central. Effect of Bupropion SR on the Quality of Life of Elderly Depressed Patients With Comorbid Medical Disorders The takeaway is that while the formal FDA maximum is 450 mg, most elderly patients end up on substantially less, and pushing toward the ceiling carries more risk in this group because of slower clearance and metabolite buildup.
Adolescents
Bupropion is not FDA-approved for anyone under 18, but it is sometimes prescribed off-label. Pharmacokinetic data suggest caution. Compared with adults, adolescents aged 12 to 14 showed weight-adjusted bupropion exposure roughly 78 to 85% higher than adults, with some individuals showing three- to four-fold increases in exposure. Teenagers aged 15 to 17 had exposure more similar to adults.13PubMed. Single-dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjects The researchers made a point of noting that younger adolescents cannot simply be treated as smaller adults, because the increased exposure is related to bupropion itself and not to its metabolites. Since no clinical safety and efficacy trials in adolescents exist, any use in this age group requires careful individualized judgment, and the adult maximum dose would be inappropriate for a 13-year-old.
What Happens in Overdose
Exceeding the maximum dose accidentally or intentionally can produce serious and sometimes life-threatening effects. At toxic doses, bupropion primarily affects the brain, heart, and gastrointestinal system. Neurological effects can include tremor, confusion, agitation, hallucinations, coma, and seizures.14PubMed Central. Seizures after overdoses of bupropion intake Cardiovascular effects include rapid heart rate, abnormal heart rhythms, QT prolongation, and widened QRS intervals on an ECG.15PubMed. Treatment of status epilepticus and prolonged QT after massive intentional bupropion overdose with lidocaine
In severe cases, the picture can deteriorate quickly. Case reports describe massive overdoses causing prolonged seizures that do not respond to standard medications, dangerous heart rhythms, and cardiovascular collapse requiring extreme interventions including mechanical circulatory support.16PubMed Central. Cardiovascular Collapse Requiring Veno-Arterial Extracorporeal Membrane Oxygenation and Lidocaine: A Case of Massive Bupropion Overdose The gap between the maximum therapeutic dose and a dangerous overdose is not as large as it is with some other antidepressants, which is one reason the dosing ceiling is taken seriously.
Bupropion Misuse Through Non-Oral Routes
An issue that has received growing attention is the misuse of bupropion tablets by crushing and snorting them, or in rarer cases by dissolving and injecting them. This is reported most often in correctional facilities, among people with histories of substance use, and among adolescents. When bupropion is snorted, the extended-release mechanism is destroyed, and the full dose hits the bloodstream rapidly. A review of poison center calls related to bupropion insufflation found that about 86% of patients had mild or moderate effects, but seizures occurred in roughly 20% of cases. Most people were already symptomatic by the time the poison center call was made, with no delayed effects observed.17The Journal of Emergency Medicine. The Timing of Clinical Effects of Bupropion Misuse Via Insufflation Reported to a Regional Poison Center
While most cases resolve without catastrophe, the potential for severe outcomes is real. Reports have documented refractory seizures and cardiogenic shock following nasal insufflation, including at least one fatal case.18Actas espanolas de psiquiatria. Bupropion misuse by nasal insufflation with a fatal outcome: case report and review The problem is significant enough that some correctional systems have restricted bupropion prescribing or switched to formulations that are harder to crush. If you are prescribed bupropion and someone asks to buy or borrow your tablets, this is part of why that is a bad idea beyond the obvious legal and medical reasons.
Drugs That Change Bupropion’s Effective Ceiling
Even within the approved 450 mg cap, certain other medications can raise bupropion or hydroxybupropion levels in your blood. Bupropion is metabolized primarily by CYP2B6, and drugs that inhibit that enzyme slow its clearance. Conversely, bupropion itself is a potent inhibitor of CYP2D6, which means it can raise blood levels of other drugs that rely on that enzyme for breakdown. Common examples include certain SSRIs, some beta blockers, and certain antipsychotics.
The practical implication is that your effective dose of bupropion is not just a function of how many milligrams you swallow. If you are also taking a CYP2B6 inhibitor, 300 mg of bupropion might produce blood levels that look more like 400 mg in someone not taking the interacting drug. Your prescriber should account for significant drug interactions when deciding how high to push your bupropion dose, and you should always mention all your medications, including over-the-counter ones, when bupropion dosing is being discussed.
Why Some People Feel Nothing at 300 mg
Given the genetic variability in CYP2B6 metabolism, it is not surprising that some patients reach 300 mg per day and feel little benefit. The issue may not be that the dose is too low in milligrams but that their body is producing too little hydroxybupropion from that dose. A fast metabolizer might clear bupropion so quickly that therapeutic metabolite levels are never reached at standard doses. For these individuals, pushing to 450 mg might genuinely be necessary to achieve the blood levels that a slow metabolizer reaches at 150 mg.
This is where the gap between the pharmacokinetic science and everyday clinical practice is most frustrating. The tools to measure hydroxybupropion levels and to genotype CYP2B6 exist, but they are not part of most prescribers’ standard workflow. The result is that dose adjustments are usually made based on clinical response and side effects rather than on blood levels or genetic testing. For most people, that trial-and-error approach works adequately. For the subset who are either ultra-rapid or very slow metabolizers, it can mean months of suboptimal treatment or unnecessary side effects before the right dose is found.